Generex Biotechnology
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Generex Biotechnology's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 57% to $2,661,396. Profit margin reached -1253%. Total operating expenses were $19,819,956.

Profit Margin

Generex Biotechnology Corporation (OTC:GNBT): Profit margin
2012 28.65K -9.49M -33123.72%
2013 0 -8.55M
2014 0 -1.41K
2015 0 -2.19M
2016 0 -3.22M
2017 0 -70.01M
2018 703.24K 36.33M 5166.64%
2019 6.20M -9.34M -150.58%
2020 2.66M -33.33M -1252.54%

GNBT Income Statement (2012 – 2020)

2020 2019 2018 2017 2016 2015 2014 2013 2012
Revenue
Revenue
2.66M6.20M703.24K0000028.65K
Cost of revenue
579.85K4.13M00000011.10K
Gross profit
2.08M2.06M703.24K0000017.54K
Operating exp.
Research and development
2.10M1.74M839.14K422.29K467.38K1.18M1.38M2.19M4.98M
Selling and marketing
00000000165.17K
Total operating expenses
19.81M23.15M3.19M1.59M1.90M3.88M4.39M6.12M10.04M
Operating income
-17.93M-24.34M-2.49M-1.59M-1.90M-3.88M-4.39M-6.12M-10.02M
Other income (expenses), net
-16.30M13.33M38.44M-75.23M-1.32M1.68M-321.67K-2.42M1.12M
Income before tax
-34.23M-11.00M35.94M-76.83M-3.22M-2.19M-1.41K-8.55M0
Income tax expense
-9.19M20.42M39.02M-74.49M-902.04K2.03M4.71M-1.89M0
Net income
-33.33M-9.34M36.33M-70.01M-3.22M-2.19M-1.41K-8.55M-9.49M
Earnings per share
Basic EPS
-0.46-0.140.48-2.41-0.12-0.09-0.00-0.66-1.02
Diluted EPS
-0.46-0.140.48-2.41-0.12-0.09-0.00-0.66-1.02
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source